CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
抗 CD19 CAR-T 细胞治疗 pro-B 急性淋巴细胞白血病合并重度斑块状银屑病：一例病例报告
英文原题：Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.
查看英文原题
Treatment of pro-B acute lymphoblastic leukemia and severe plaque psoriasis with anti-CD19 CAR T cells: a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本文报告一例罕见病例：一名成人前 B 急性淋巴细胞白血病（pro-B ALL）患者合并严重难治性斑块状银屑病，接受自体抗 CD19 嵌合抗原受体（CAR）T 细胞治疗。该 18 岁男性既往有轻度斑块状银屑病病史 1 年，随后确诊 pro-B ALL。诱导化疗后，银屑病开始恶化。患者全身出现广泛红斑和脱屑，膝部及肘部斑块状银屑病严重，且对局部治疗无反应。CAR-T 细胞治疗不仅使患者达到深度完全缓解（CR），还使其皮损完全消退。该成功治疗支持 B 细胞与银屑病之间可能存在致病联系，并提示 CAR-T 可为克服难治性银屑病提供新的选择。
展开英文摘要原文
We report on a rare case of adult pro-B acute lymphoblastic leukemia (pro-B ALL) accompanied with severe refractory plaque psoriasis treated using autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. An 18-year-old man with a known history of mild plaque psoriasis for 1 year was diagnosed with pro-B ALL. After induction chemotherapy, his psoriasis began to worsen.
Extensive erythema and desquamation developed on the whole body, with severe plaque psoriasis on the knees and elbows, which did not respond to topical therapy. The application of CAR T-cell therapy not only enabled the patient to achieve deep complete remission (CR) but also allowed his skin lesions to completely subside. This successful treatment supports a potential pathogenic link between B cells and psoriasis, which could provide a new option for overcoming refractory psoriasis.
论文信息
- 作者
- Zhang A、Zhang G、Yang H、Gong B、Li S、Wei N、Xue H、Wei H
- 单位
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.China
- 文献类型
- 病例报告
- 期刊
- Frontiers in immunology2025
- 原文标识
- PubMed 40098975 · DOI 10.3389/fimmu.2025.1529745
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →